LAURA Study Part 2: Radiation Oncology Perspective

This episode of Lung Cancer Considered covers the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC, based on the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians.